Evidence map›Paper›PMID 42619739›Full record

ArticlebioRxiv : the preprint server for biology2026

Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer.

Brett A Schroeder, Jae Choi, Alejandro A Schäffer, Michael Nirula, Yingying Cao, Yang Zhang, Anna-Lena Meinhardt, Hyeokjun Kwon, Hyerim Park, Sangin Lee and 28 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Brett A SchroederDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jae ChoiDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Alejandro A SchäfferCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Michael NirulaDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yingying CaoCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Yang ZhangDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Anna-Lena MeinhardtDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hyeokjun KwonDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Hyerim ParkDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Sangin LeeDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Hyo Jin ShinDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Hee Geon ParkDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Hobin YangCollege of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.
Sungyoul HongCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Parth DesaiDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Donna ButcherMolecular Histopathology Laboratory, Laboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Pattara SukprasertDatabricks, San Francisco, CA, USA.
Binbin WangCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
D Nathan BierySchool of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
Rajaa El MeskiniCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Devon AtkinsonCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Laura L BasselCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Zoe Weaver OhlerCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Yue HuangDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Allison L HuntWomen's Health Integrated Research Center, Inova Women's Service Line, Inova Health System, Annandale, VA, USA.
Tamara AbulezHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Nicholas W BatemanHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Thomas P ConradsWomen's Health Integrated Research Center, Inova Women's Service Line, Inova Health System, Annandale, VA, USA.
Ross LakeLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Stephen M HewittLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sunghyun HongR&D Center, ABION Inc., Seoul, Republic of Korea.
Jaemun KimR&D Center, ABION Inc., Seoul, Republic of Korea.
Seung Hwa JungR&D Center, ABION Inc., Seoul, Republic of Korea.
Ho Jin LeeSNU Future Innovation Institute, Seoul National University, Seoul 08826, Republic of Korea.
Saehyung LeeR&D Center, ABION Inc., Seoul, Republic of Korea.
Young Kee ShinDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
Eytan RuppinCancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anish ThomasDevelopmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) remains a highly lethal disease with limited targetable surface antigens beyond delta-like ligand 3 (DLL3). We sought to systematically identify and validate tumor-selective cell-surface targets in relapsed SCLC. To this end, we developed an integrated proteogenomic pipeline combining single-cell RNA sequencing, combinatorial optimization, mass spectrometry-based proteomics, and immunohistochemistry to systematically map the SCLC surfaceome of 49 tumors across 25 patients with relapsed SCLC. Using this approach we found claudin-3 (

Identifiers

PMID42619739
PMCPMC13484066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.